Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience

BACKGROUND: Fingolimod (FTY) and dimethyl fumarate (DMF) are multiple sclerosis (MS) oral therapies that became available in 2010 and 2013, respectively. OBJECTIVE: The objective of this article is to compare discontinuation rates, efficacy, and adverse events (AEs) of FTY and DMF over two years. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollmer, Brandi, Nair, Kavita V, Sillau, Stefan H, Corboy, John, Vollmer, Timothy, Alvarez, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564884/
https://www.ncbi.nlm.nih.gov/pubmed/28839949
http://dx.doi.org/10.1177/2055217317725102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564884/
https://www.ncbi.nlm.nih.gov/pubmed/28839949
http://dx.doi.org/10.1177/2055217317725102

Ejemplares similares